Presenting Grabody-B non-clinical data in an oral presentation at 9:00 a.m. on July 28 (local time)
[by Kang, In Hyo] ABL Bio, a company specializing in dual antibodies, announced on July 24 that it will participate in the ‘Alzheimer’s Association International Conference (AAIC) 2025,’ taking place in Toronto, Canada, from July 27 to 31 (local time), where it will present its blood-brain barrier (BBB) shuttle platform, ‘Grabody-B’.
AAIC is the world’s largest academic conference dedicated to Alzheimer’s disease, encompassing a wide range of topics, including basic science, diagnosis, treatment, prevention, and disease management. Each year, the event brings together pharmaceutical and 스피드 바카라 사이트technology experts, as well as medical professionals from around the world, to present research findings and explore diverse collaboration opportunities.
During the conference, ABL 스피드 바카라 사이트 will deliver an oral presentation on the non-clinical data of Grabody-B under the theme, ‘Grabody-B, an IGF1R-targeting Molecular Shuttle, Sustains Brain Penetration of Therapeutic Antibody in Aged Mice by Multiple, Novel Transcytosis Pathways.’ The presentation is scheduled for 9:00 a.m. on July 28 (local time).
The BBB acts as a protective shield that prevents harmful substances and external factors from entering the brain, but it has long been regarded as a significant challenge in the development of treatments for degenerative brain disorders. Since the multinational pharmaceutical company Roche reported positive early clinical data in 2023 for ‘trontinemab,’ an amyloid beta (Aβ) antibody using BBB shuttle technology, global interest in BBB shuttle platforms has increased rapidly.
ABL 스피드 바카라 사이트's Grabody-B is a platform technology designed to target the 'Insulin-like Growth Factor 1 Receptor (IGF1R),' facilitating the efficient passage of drugs through the BBB for delivery to the brain. In April, ABL 스피드 바카라 사이트 entered into a technology transfer agreement for the Grabody-B platform with the multinational pharmaceutical company GlaxoSmithKline (GSK), valued at up to KRW 4.1 trillion (£2.14 billion). This deal includes an upfront payment and short-term milestone payments (staged technology fees) totaling KRW 148 billion (£77.1 million).
“Since the clinical results of trontinemab were announced, interest in BBB shuttle technology has surged, and attention toward Grabody-B has also been increasing. We are particularly witnessing strong global interest following the technology transfer agreement with GSK,” said Lee Sang-hoon, CEO of ABL 스피드 바카라 사이트. “In this presentation, we will highlight the diverse brain delivery pathways of Grabody-B identified through non-clinical studies using mouse models. We look forward to your interest and anticipation,” he added.